琥珀酸美托洛尔缓释片治疗心梗后室性心律失常的效果观察  

Observation on the therapeutic effect of metoprolol succinate sustained-release tablets on ventricular arrhythmias after myocardial infarction

作　　者：崔俊朋 张顺祥 CUI Jun-peng;ZHANG Shun-xiang(Cardiovascular Medicine Department,Guangrao County People's Hospital,Dongying 257300,China)

机构地区：[1]广饶县人民医院心血管内科,257300

出　　处：《中国实用医药》2024年第17期1-5,共5页China Practical Medicine

摘　　要：目的评价分析琥珀酸美托洛尔缓释片治疗心肌梗死(心梗)后室性心律失常的效果。方法48例心梗后室性心律失常患者,采取随机数字表法分为对照组及观察组,每组24例。对照组患者采用阿司匹林、阿托伐他汀和卡托普利片治疗,观察组在对照组基础上采用琥珀酸美托洛尔缓释片治疗。比较两组治疗效果,心理状态[焦虑自评量表(SAS)、抑郁自评量表(SDS)评分],治疗依从性,不良反应发生情况,生活质量,心电图指标[QT间期离散度(QTd)及校正后QT间期离散度(QTcd)]。结果观察组总有效率91.67%相比对照组的66.67%显著更高(P<0.05)。治疗后,观察组的SAS评分(33.28±4.02)分、SDS评分(31.08±4.15)分较对照组的(41.01±6.11)、(39.51±5.21)分明显更低(P<0.05)。观察组的治疗依从性95.83%比对照组的66.67%更高(P<0.05)。观察组的不良反应发生率4.17%明显较对照组的25.00%低(P<0.05)。观察组的心理功能、生理功能、社会关系评分及总分分别为(78.80±2.13)、(76.53±3.56)、(79.30±4.17)、(78.29±3.60)分,较对照组的(69.85±2.88)、(65.79±3.93)、(67.90±4.74)、(68.19±3.94)分明显更高(P<0.05)。治疗后,观察组的QTd(40.18±1.62)ms、QTcd(53.28±4.55)ms较对照组的(55.21±4.51)、(68.51±5.25)ms明显更短(P<0.05)。结论通过实施琥珀酸美托洛尔缓释片治疗,可以有效地改善心梗后室性心律失常患者的心理状态,提高患者的治疗效果和治疗依从性,这一方法在临床实践中具有显著的应用价值。Objective To evaluate and analyze the effect of metoprolol succinate sustained-release tablets on ventricular arrhythmias after myocardial infarction.Methods 48 patients with ventricular arrhythmias after myocardial infarction were selected for this study.All study subjects were divided into a control group and an observation group using a random number table method,with 24 cases in each group.The control group was treated with aspirin,atorvastatin,and captopril tablets,and the observation group was also treated with metoprolol succinate sustained-release tablets.Both groups were compared in terms of therapeutic effect,psychological state[Self-Rating Anxiety Scale(SAS)and Self-Rating Depression Scale(SDS)scores],treatment compliance,adverse reactions,quality of life,electrocardiogram indicators[QT interval dispersion(QTd)and corrected QT interval dispersion(QTcd)].Results The total effective rate of 91.67%in the observation group was significantly higher than 66.67%in the control group(P<0.05).After treatment,the observation group had SAS score of(33.28±4.02)points and SDS score of(31.08±4.15)points,which were significantly lower than(41.01±6.11)and(39.51±5.21)points in the control group(P<0.05).The treatment compliance of the observation group was 95.83%,which was higher than 66.67%of the control group(P<0.05).The incidence of adverse reactions of 4.17%in the observation group was significantly lower than 25.00%in the control group(P<0.05).In the observation group,the scores of psychological function,physiological function,social relation and total score were(78.80±2.13),(76.53±3.56),(79.30±4.17)and(78.29±3.60)points,which were ignificantly higher than(69.85±2.88),(65.79±3.93),(67.90±4.74)and(68.19±3.94)points in the control group(P<0.05).After treatment,the observation group had QTd of(40.18±1.62)ms and QTcd of(53.28±4.55)ms,which were significantly shorter than(55.21±4.51)and(68.51±5.25)ms in the control group(P<0.05).Conclusion The implementation of metoprolol succinate sustained-release table

关 键 词：心肌梗死后室性心律失常 琥珀酸美托洛尔缓释片 心理状态 依从性 

分 类 号：R542.22[医药卫生—心血管疾病] R541.7[医药卫生—内科学]